The latest price target for Aptevo Therapeutics (NASDAQ:APVO) was reported by Piper Sandler on May 13, 2022. The analyst firm set a price target for $20.00 expecting APVO to rise to within 12 months (a possible 3490.02% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Aptevo Therapeutics (NASDAQ:APVO) was provided by Piper Sandler, and Aptevo Therapeutics maintained their overweight rating.

There is no last upgrade for Aptevo Therapeutics

There is no last downgrade for Aptevo Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aptevo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aptevo Therapeutics was filed on May 13, 2022 so you should expect the next rating to be made available sometime around May 13, 2023.

While ratings are subjective and will change, the latest Aptevo Therapeutics (APVO) rating was a maintained with a price target of $69.00 to $20.00. The current price Aptevo Therapeutics (APVO) is trading at is $0.56, which is out of the analyst’s predicted range.